tAN for Alcoholism

HO
CB
Overseen ByCaroline Benner
Age: 18 - 65
Sex: Any
Trial Phase: Academic
Sponsor: Spark Biomedical, Inc.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores a new treatment called transcutaneous auricular neurostimulation (tAN) to help individuals with alcohol use disorder (AUD) manage withdrawal symptoms. Participants will wear a tAN device for a few hours each day to determine if it reduces withdrawal severity and alters brain activity related to cravings and mood. The study includes a treatment group receiving active tAN and a placebo group with a sham device. It suits those with moderate to severe AUD experiencing withdrawal symptoms. As an unphased trial, this study allows participants to contribute to groundbreaking research that could lead to new treatment options for AUD.

Do I have to stop taking my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators.

What prior data suggests that this tAN device is safe for treating alcohol use disorder?

Research has shown that transcutaneous auricular neurostimulation (tAN) is generally safe for people. One study found that tAN effectively reduces symptoms of opioid withdrawal. This research led to FDA clearance, indicating a strong safety record.

While researchers continue to study tAN's effectiveness for alcohol withdrawal, its safety in similar situations is promising. Participants in past studies have typically tolerated tAN well, with few side effects reported. For those considering joining a trial, these findings suggest that tAN could be a safe option.12345

Why are researchers excited about this trial?

Transcranial alternating current stimulation (tAN) is unique because it offers a non-invasive approach to treating alcoholism by using gentle electrical currents to stimulate the brain. Unlike current treatments, which often include medications like disulfiram or naltrexone, and behavioral therapies, tAN directly targets brain activity patterns associated with addiction. Researchers are excited about tAN because it has the potential to enhance traditional therapies by modulating neural circuits without the side effects typically associated with medication. Additionally, the possibility of combining tAN with a patient's standard care could offer a more comprehensive approach to managing alcoholism.

What evidence suggests that the tAN device is effective for alcohol use disorder?

Research shows that transcutaneous auricular neurostimulation (tAN) might help manage symptoms when people stop drinking alcohol. One study found that similar noninvasive nerve stimulation methods reduced distress in people with alcohol use disorder. Another study suggested that stimulating the ear's vagus nerve improved depression and sleep in those who had stopped drinking. These early findings suggest tAN might work by altering brain connectivity, potentially aiding in managing withdrawal symptoms. In this trial, participants will receive either active tAN or sham tAN to further study its benefits in alcohol use disorder. These studies offer promising signs.36789

Who Is on the Research Team?

NK

Navid Khodaparast, PhD

Principal Investigator

Spark Biomedical, Inc.

Are You a Good Fit for This Trial?

This trial is for individuals with alcohol use disorder (AUD) who are experiencing withdrawal. They'll be at The Menninger Clinic for a 5-day detox, where they'll wear the tAN device. Participants must meet certain health criteria and will be randomly assigned to either the active treatment or a placebo group.

Inclusion Criteria

Be able to provide written informed consent
I am between 18 and 64 years old.
Demonstration of at least moderate risk of alcohol use at screening using the WHO-ASSIST
See 6 more

Exclusion Criteria

Do not meet the pre-screening MRI questions provided by the Center for Advanced MR Imaging (CAMRI) at BCM
In the opinion of the clinician and the research team at admission, be expected to fail to complete the study protocol due to probably relocation from The Menninger Clinic area or not tolerable to receive tAN
Current use of tobacco
See 2 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1 day
1 visit (in-person)

Baseline

Baseline assessments including clinical measures and MRI scans are conducted

1 day
1 visit (in-person)

tAN Treatment

Participants undergo a 5-day tAN treatment to attenuate alcohol withdrawal syndrome and alter resting state functional connectivity

5 days
Daily visits (in-person)

Post tAN Treatment

Post-treatment assessments including clinical measures and MRI scans are conducted

1 day
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • tAN

Trial Overview

The study tests if a 5-day transcranial auricular nerve stimulation (tAN) can ease alcohol withdrawal symptoms and change brain connectivity in AUD patients. It compares an active tAN treatment against a sham version, monitoring effects through clinical assessments and MRI scans before and after treatment.

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Placebo Group

Group I: Active tANExperimental Treatment1 Intervention
Group II: Sham tANPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Spark Biomedical, Inc.

Lead Sponsor

Trials
14
Recruited
560+

The Menninger Clinic

Collaborator

Baylor College of Medicine

Collaborator

Trials
1,044
Recruited
6,031,000+

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Collaborator

Trials
865
Recruited
1,091,000+

Citations

Use of tAN® in Alcohol Withdrawal Management

Transcutaneous Auricular Neurostimulation has proven effective in reducing symptoms of opioid withdrawal and it is hypothesized that with the similar withdrawal ...

Effect of Transcutaneous Auricular Vagus Nerve Stimulation ...

These results suggest that taVNS could improve the depression symptoms and sleep quality in alcohol-dependent patients after withdrawal.

Neuromodulation for Treating Substance Use Disorders

For alcohol use disorder treatment, rTMS studies showed promising results, with many studies showing multi-sessions produce significantly ...

Noninvasive Vagus Nerve Stimulation Reduces ...

Noninvasive Vagus Nerve Stimulation Reduces Withdrawal-Related Affective Distress and Improves Functional Outcomes in Alcohol Use Disorder: A ...

Auricular transcutaneous vagus nerve stimulation for ...

Here, we discuss the potential use of auricular transcutaneous vagus nerve stimulation (atVNS) as an ADD-ON intervention in AUD.

NCT07281261 | tAN for Substance Use Disorder

The study will involve a 5-day tAN treatment to attenuate alcohol withdrawal syndrome (AWS) and alter resting state functional connectivity ...

Delivering transcutaneous auricular neurostimulation (tAN) to ...

Results demonstrate tAN is a safe and effective non-opioid approach for reducing symptoms of OWS. This study supported an FDA clearance.

Effect of Transcutaneous Auricular Vagus Nerve ...

The present study is the first to demonstrate that taVNS could improve depression and sleep quality in patients with alcohol dependence after withdrawal.

Auricular transcutaneous vagus nerve stimulation for ...

Here, we discuss the potential use of auricular transcutaneous vagus nerve stimulation (atVNS) as an ADD-ON intervention in AUD.